ABSTRACT TEMPLATE for Company Presentations

o **Investment Rational**
Terrapeutics focuses on the unexplored potential of natural small molecules with respect to drug targets that are considered "undruggable". The company's discovery platform is initially targeting RAS inhibitors and bacteria resistant antibiotics. The company successfully completed POCs in these areas and signed a strategic collaboration agreement to co-develop its discovered molecules with HIPS, a world leader in this space

o **Business Strategy**

We will utilize its technology to screen and isolate therapeutic natural molecules that can become drugs that aim for undruggable targets. First, we will leverage our collaboration with HIPS to discover new antibiotics for resistant bacteria and RAS inhibitors. Next, we will develop additional lab automation and AI/ML tools to scale our discovery platform to generate multiple drug candidates which will be the basis for JV agreements with Pharma companies

o **Core Technology**

Terrapeutics developed a novel technology that screens the full potential of naturally produced molecules. Soil bacteria communities can synthesize drug-like molecules far beyond what is known to date. Using synthetic biology, we challenge the resident bacteria in their natural environment so that its community's survival depends on the synthesis of an inhibitor to a drug target of our choice.

o **Product Profile/Pipeline**
The company's first focus is on antibiotic and RAS inhibiting molecules. Both being undruggable targets, their total addressable market is enormous, especially for RAS inhibitors that are drivers of 25-30% of the known cancer types. In addition to our collaboration with HIPS, we plan to seek additional agreements with pharma companies to leverage our unique platform to co develop our lead discoveries into drugs

o **What's Next?**
We are currently raising $3M seed funds to achieve the following goals in the next 24 months:

- Isolate and identify RAS inhibitors and new antibiotics

- Develop a panel of patented RAS inhibitors targeting multiple oncogenic mutations

- Develop lab automation and AI/ML based computation tools to scale up our platform